Astellas' Veoza™ (fezolinetant) approved by European Commission for treatment of Vasomotor Symptoms (VMS) associated with menopause
VMS, also known as hot flushes and/or night sweats, is a common symptom of menopause
Source: imt.ie
Biopharma Development News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Biopharma Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Biopharma Development Today - Breaking & Trending Today
Astellas' VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause
First-in-class treatment option reduces number and intensity of hot flashes and night sweats TOKYO, Dec. 10, 2023 /PRNewswire/ -- Astellas Pharma Inc. today announced the European Commission on...
Source: marketscreener.com
Astellas Pharma's treatment for hot flashes and sweats approved
A treatment option to reduce the number and intensity of hot flashes and night sweats associated with menopause has been approved by the European Commission (EC).
Source: outsourcing-pharma.com
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity of moderate to severe vasomotor symptoms due to menopause and patient-reported sleep disturbance at 24 weeks Women considered unsuitable included those with contraindications, who are averse to taking, have stopped taking or have conditions that suggest caution in using hormone therapy Results will support health technology a...
Source: webwire.com
Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy
Phase 3b DAYLIGHT study being presented at ESG 2023 demonstrated fezolinetant 45 mg achieved statistically significant reductions in the frequency and severity...
Source: prnewswire.com